Piedmont Oncology Unveils Sherron Berg Early Detection Pancreatic Cancer Program

Transformational Gift Unveils a Groundbreaking Program

Piedmont Oncology has recently announced a landmark philanthropic donation aimed at enhancing its Early Detection Pancreatic Cancer Clinic (EDC). This generous contribution will not only bolster clinical operations but will also create an endowed medical director position dedicated to the clinic. In honor of this significant investment, the clinic will now be recognized as the Sherron Berg Early Detection Pancreatic Cancer Program. Furthermore, the associated surgical facility will be named the Sherron Berg Surgical Oncology and Hepato-Pancreato Biliary (HPB) Surgery Clinic.

Dr. Andrew Page, appointed as the Sherron Berg Endowed Medical Director, expressed profound gratitude for the donation that will have a transformative impact on their endeavors. He emphasized that the name Sherron Berg represents inspiration for him and his colleagues in their ongoing fight against pancreatic cancer, a disease notorious for its aggressiveness and low survival rates.

The Sherron Berg program is not merely a tribute but a testament to the shared vision of the Berg family and Piedmont Oncology, focusing on early detection and treatment options for those affected by this challenging illness. In 2023, Sherron Berg was diagnosed with pancreatic cancer at stage two, necessitating a Whipple surgery conducted by Dr. Page, aimed at increasing her chances for successful treatment. The newly established program aims to extend similar possibilities to other patients in Georgia, exemplifying the shared commitment to combating pancreatic cancer.

The EDC commenced operations in November 2025, making it the first of its kind in Georgia. This center is designed to deliver comprehensive risk assessments, bolster awareness of pancreatic cancer, and enhance accessibility for both referring clinicians and patients, ultimately spearheading vital research collaborations aimed at improving treatment outcomes.

According to the American Cancer Society, pancreatic cancer represents one of the most formidable challenges in healthcare, boasting a mere 13 percent five-year survival rate across all stages. Tragically, despite being relatively rare, it ranks as the fourth-leading cause of cancer-related deaths in the United States. The grim statistics underline the urgency of facilitating early detection and offering effective treatment solutions.

For individuals wishing to contribute to the Sherron Berg Early Detection Pancreatic Cancer Program, donations can be made through give.piedmont.org/pancreas. Access to the clinic is available through either physician referrals or self-referrals, ensuring that more patients can take proactive steps in their healthcare journey.

In summary, the establishment of the Sherron Berg Early Detection Pancreatic Cancer Program represents a beacon of hope in the ongoing struggle against one of the deadliest cancers known to humanity. With robust financial backing and a dedicated team of professionals, Piedmont Oncology is poised to make significant strides in advancing treatment options and improving early detection methodologies, thus enhancing survival rates and quality of life for patients facing this daunting diagnosis.